IGF1 and acromegaly: When comparing baseline IGF-1 levels with the biochemical control of acromegaly immediately before PAS therapy, the entire cohort exhibited a median reduction of −51% in IGF-1 levels (from 753 μg/L to 416 μg/L; p < 0.001).